natgillin/translations-raw huggingface dataset:
Sammenlignet med en fastdosiskombination af indacaterol og glycopyrronium forbedrede Riarify den gennemsnitlige FEV1 inden dosering i løbet af den 52-ugers behandlingsperiode med 22 ml (p = 0,018). 
Compared with a fixed combination of indacaterol and glycopyrronium, Riarify improved average pre-dose FEV1 over the 52-week treatment period by 22 mL (p=0.018).
Diarré1, mundtørhed, dysfagi1, kvalme, dyspepsi1, brændende fornemmelse af læberne1, tandkaries1, (aftøs) stomatitis 
Diarrhoea1, dry mouth, dysphagia1, nausea, dyspepsia1, burning sensation of the lips1, dental caries1, (aphthous) stomatitis
Hvis du har glemt at bruge Riarify 
If you forget to use Riarify
180 pust 
180 actuations
Ved brug af systemisk og topikalt kortikosteroid kan der blive indberettet synsforstyrrelser. 
Visual disturbance may be reported with systemic and topical corticosteroid use.
Der blev ikke observeret nogen forskelle, når Riarify blev sammenlignet med den ekstemporære trippelkombination bestående af beclometasondipropionat og formoterol fastdosiskombination plus tiopropium (hyppigheden af moderate/svære eksacerbationer: 0,46 versus 0,45 hændelser pr. patient/år). 
No differences were observed when comparing Riarify with the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (moderate/severe exacerbation rate: 0.46 versus 0.45 events per patient/year).
Hver gang du trykker på trykbeholderen, leveres et pust af medicin, og dosistælleren vil tælle ned med en. 
Each time you press the pressurised container, a puff of medicine is released and the counter will count down by one.
Hold din inhalator lodret med mundstykket forneden Sørg for, at mundstykket vender væk fra dig, og tryk med en fast hånd ned på trykbeholderen, for at levere et pust 
Hold your inhaler upright with the mouthpiece at the bottom Direct the mouthpiece away from yourself and firmly press the pressurised container to release one puff
Da formoterol primært elimineres via levermetabolismen, kan der imidlertid forventes en øget eksponering hos patienter med svært nedsat leverfunktion. 
The pharmacokinetics of formoterol has not been studied in patients with hepatic impairment; however, as formoterol is primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe hepatic impairment.
• uklar linse i øjnene (grå stær). 
• clouding of the lens of your eyes (cataract).
Trykbeholder er indsat i en polypropylen inhalator med et indbygget mundstykke og en dosistæller (60 pust eller 120 pust pr. trykbeholder) eller en dosisindikator (180 pust pr. trykbeholder), og den leveres med et polypropylenlåg til mundstykket. 
The pressurised container is inserted in a polypropylene inhaler which incorporates a mouthpiece and a dose counter (60 actuations or 120 actuations per pressurised container) or dose indicator (180 actuations per pressurised container) and is provided with a polypropylene mouthpiece cap.
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 60 pust 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 60 actuations
Trykbeholderen må ikke perforeres. 
Do not pierce the pressurised container.
For en sikkerheds skyld bør Riarify derfor undgås under graviditeten og fødsel. 
Therefore, as a precautionary measure, it is preferable to avoid the use of Riarify during pregnancy and during labour.
Farmakokinetikken af beclometasondipropionat hos patienter med nedsat leverfunktion er imidlertid ikke undersøgt, da beclometasondipropionat gennemgår en meget hurtig metabolisme via esteraseenzymer i intestinalvæsken, serum, lunger og lever, så der dannes de mere polære produkter beclometason-21-monopropionat, beclometason-17-monopropionat og beclometason. 
The pharmacokinetics of beclometasone dipropionate in patients with hepatic impairment has not been studied, however, as beclometasone dipropionate undergoes a very rapid metabolism via esterase enzymes present in intestinal fluid, serum, lungs and liver to form the more polar products beclometasone 21-monopropionate, beclometasone 17-monopropionate and beclometasone, hepatic impairment is not expected to modify the pharmacokinetics and safety profile of beclometasone dipropionate.
Sløret syn1 (se også pkt. 
Vision, blurred1 (see also section 4.4)
Lige efter de begynder at trække vejret ind, skal patienterne med en fast hånd trykke ned foroven på trykbeholderen for at levere et pust. 
Immediately after starting to breathe in, patients should firmly press down on the top of the pressurised container to release one puff.
TRIBUTE var et 52-ugers aktivt kontrolleret studie, der sammenlignede Riarify med en fastdosiskombination af indacaterol/glycopyrronium 85/43 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (1.532 randomiserede patienter). 
TRIBUTE was a 52-week activecontrolled study comparing Riarify with a fixed combination of indacaterol/glycopyrronium 85/43 micrograms inhalation powder, hard capsule, one inhalation once daily (1,532 randomised patients).
Hos patienter med svært nedsat leverfunktion må Riarify kun anvendes, hvis den forventede fordel opvejer den mulige risiko (se pkt. 
In patients with severe hepatic impairment, Riarify should be used only if the expected benefit outweighs the potential risk (see section 5.2).
TRILOGY-studiet sammenlignede Riarify med en fastdosiskombination af beclometasondipropionat og formoterol 100/6 mikrogram givet som to inhalationer to gange dagligt (1.368 randomiserede patienter). 
Study TRILOGY compared Riarify with a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily (1,368 randomised patients).
• en beholder, der leverer 120 pust 
• a container providing 120 puffs
Glycopyrronium: glaukom, atrieflimmer, takykardi, palpitationer, mundtørhed, tandkaries, dysuri, urinretention, urinvejsinfektion. 
Glycopyrronium: glaucoma, atrial fibrillation, tachycardia, palpitations, dry mouth, dental caries, dysuria, urinary retention, urinary tract infection.
• hvis du har lever- eller nyresygdomme. 
• if you have any disease of your liver or kidneys.
Beclometasondipropionat: pneumoni, orale svampeinfektioner, svampeinfektion i de nedre luftveje, dysfoni, halsirritation, hyperglykæmi, psykiske sygdomme, nedsat kortisol, sløret syn. 
Beclometasone dipropionate: pneumonia, oral fungal infections, lower respiratory tract infection fungal, dysphonia, throat irritation, hyperglycaemia, psychiatric disorders, cortisol decreased, blurred vision.
Efter udlevering kan inhalatoren opbevares ved temperaturer op til 25 °C i maksimalt 2 måneder. 
After dispensing, the inhaler may be stored at a temperature up to 25°C for a maximum of 2 months.
Hvis du har et svagt greb, kan det være nemmere at holde inhalatoren med begge hænder. 
If you have a weak grip, it may be easier to hold the inhaler with both hands: hold the upper part of the inhaler with both index fingers and its lower part with both thumbs.
• øget niveau af nogle af bestanddelene i blodet: af glucose, C-reaktivt protein, af antallet af blodplader, af frie fedtsyrer eller af ketoner. 
• increase in the level of some constituents of your blood: glucose, C-reactive protein,
• beclometasondipropionat 
• beclometasone dipropionate,
Sådan skal du bruge din inhalator 
How to use your inhaler
Behandling med beta2-agonister kan føre til potentielt alvorlig hypokaliæmi. 
Potentially serious hypokalaemia may result from beta2-agonist therapy.
Opbevares ved 25 °C i maksimalt 4 måneder. 
Store at 25°C for a maximum of 4 months.
Med relation til glycopyrronium 
Related to glycopyrronium
Riarify er en inhalationsspray, opløsning. 
Riarify is a pressurised inhalation, solution.
Virkninger på lungefunktionen 
Effects on lung function
Forhøjet C-reaktivt protein1, forhøjet antal trombocytter1, forhøjet niveau af frie fedtsyrer1, forhøjet insulinindhold i blodet1, forhøjet ketonindhold i blodet1, nedsat kortisol1 
C-reactive protein increased1, platelet count increased1, free fatty acids increased1, blood insulin increased1, blood ketone body increased1, cortisol decreased1
Lige efter du begynder at trække vejret ind, skal du med en fast hånd trykke ned foroven på trykbeholderen for at levere et pust. 
Just after starting to breathe in, press down firmly on the top of the pressurised container to release one puff.
Patienterne skal holde inhalatoren lodret med beholderen øverst, og placere mundstykket mellem tænderne uden at bide i det. Læberne skal lukkes rundt om mundstykket med en flad tunge nedenunder. 
Hold the inhaler upright with the mouthpiece at the bottom and place the mouthpiece between your teeth without biting it. Then place your lips around the mouthpiece, with the tongue flat under it.
Anvendelsen af Riarify til patienter med svært nedsat nyrefunktion eller nyresygdom i slutstadiet der kræver dialyse, især hvis det er forbundet med en signifikant vægttab, bør kun overvejes, hvis den forventede fordel opvejer den mulige risiko (se pkt. 
Use of Riarify in patients with severe renal impairment or end-stage renal disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see section 4.4 and section 5.2).
Opbevares ved 25 °C i maksimalt 2 måneder. 
Store at 25°C for a maximum of 2 months.
Hyperæmi1, rødme1, hypertension 
Hyperaemia1, flushing1, hypertension
- når du bruger beholderen, der leverer 180 pust 
- when using the container providing 180 puffs
Brug af inhalatoren 
Use of the inhaler
Hypersomni 
Hypersomnia
- når du bruger beholderen, der leverer 60 pust 
- when using the container providing 60 puffs
Derfor rådes der til forsigtighed, når andre beta-adrenerge lægemidler ordineres samtidigt med formoterol. 
Concomitant use of other beta-adrenergic medicinal products can have potentially additive effects; therefore, caution is required when other beta-adrenergic medicinal products are prescribed concomitantly with formoterol.
TRISTAR var et 26-ugers, åbent, aktivt kontrolleret studie, der sammenlignede Riarify med en ekstemporær kombination bestående af en fastdosiskombination af fluticason/vilanterol 92/22 mikrogram inhalationspulver, en inhalation én gang dagligt plus tiotropium 18 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (1.157 randomiserede patienter). 
TRISTAR was a 26-week active-controlled open label study comparing Riarify with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients).
• løbende eller tilstoppet næse og nysen 
• runny or stuffy nose and sneezing
Hoste, produktiv hoste1, halsirritation, epistaxis1 
Cough, productive cough1, throat irritation, epistaxis1
Sammenlignet med tiotropium forbedrede Riarify FEV1 før dosering med 51 ml efter 26 ugers behandling og med 61 ml efter 52 ugers behandling. 
Compared with tiotropium, Riarify improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment.
1 trykbeholder med 180 pust. 
1 pressurised container of 180 actuations.
FEV1 før dosering 
Pre-dose FEV1
Vækstretardation1 
Growth retardation1
Trykbeholder med 120 og 180 pust: 
120 and 180 actuation pressurised container:
1 trykbeholder med 120 pust. 
1 pressurised container of 120 actuations.
1 trykbeholder med 60 pust. 
1 pressurised container of 60 actuations.
Øvrige indholdsstoffer: vandfrit ethanol, saltsyre, drivmiddel: norfluran. 
The other ingredients are: ethanol anhydrous, hydrochloric acid, propellant: norflurane.
Sæt beskyttelseslåget på igen efter brug. 
After use, replace the protective cap.
Virkning af nedsat nyrefunktion 
Effect of renal impairment
• tør i halsen 
• dry throat
Inhalationsspray, opløsning. 
Pressurised inhalation, solution.
- når du bruger beholderen, der leverer 120 pust 
- when using the container providing 120 puffs
Efter inhalation skal patienterne skylle munden eller gurgle med vand uden at synke det eller børste tænder (se pkt. 
After inhaling, patients should rinse their mouth or gargle with water without swallowing it or brush their teeth (see sections 4.2 and 4.4).
Du må ikke anvende Riarify under amning. 
You should not use Riarify during breast-feeding.
Glycopyrronium virker ved at blokere den bronkokonstiktive virkning af acetylcholin på de glatte muskelceller i luftvejene, og derved dilatere dem. Glycopyrroniumbromid er en muskarinreceptor med en høj affinitet, og der er blevet påvist en selektivitet over for humane M3-receptorer, der var 4-gange større end for humane M2-receptorer. 
Glycopyrronium bromide is a high affinity muscarinic receptor antagonist with a greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor as it has been demonstrated.
• uregelmæssigt hjerteslag 
• irregular heart beat
Før trykbeholderne med 60, 120 eller 180 pust primes, skal der stå henholdsvis. 
Before priming the 60, 120 or 180 actuation pressurised containers, the counter/indicator should read 61, 121 or 180, respectively.
Sørg for ikke at tabe inhalatoren, da det kan få dosistælleren til at tælle ned. 
Take care not to drop the inhaler as this may cause the counter to count down.
Priming af inhalatoren 
Priming the inhaler
Patienterne skal fjerne beskyttelseslåget fra mundstykket og kontrollere, at mundstykket er rent og uden støv og snavs eller andre fremmedlegemer. 
IMPORTANT: steps 2 to 5 should not be performed too quickly: Patients should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.
Trykbeholder med 60 pust: 
60 actuation pressurised container:
Sammenlignet med en fastdosiskombination af indacaterol og glycopyrronium nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 15 % (hyppighed: 0,50 versus 0,59 hændelser pr. patient/år, p = 0,043). 
Compared with a fixed combination of indacaterol and glycopyrronium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043).
Trombocytopeni1 
Thrombocytopenia1
Desuden bør en langvarig administration af Riarify sammen med andre lægemidler, der indeholder antikolinergika, ikke anvendes, på grund af den antikolinerge virkning af glycopyrronium (se pkt. 
Additionally, due to the anticholinergic effect of glycopyrronium, the long-term co-administration of Riarify with other anticholinergic-containing medicinal products is not recommended (see section 4.5).
• åndenød eller stakåndethed 
• feeling breathless or short of breath
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Riarify FEV1 2-timer efter dosering med 117 ml efter 26 ugers behandling, og med 103 ml efter 52 ugers behandling (p < 0,001). 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001).
Efter priming skal der stå 60, 120 eller 180 på dosistælleren/indikatoren. 
After priming, the counter/indicator should read 60, 120 or 180.
• svampeinfektioner i skeden 
• fungal infections of the chest
Beclometason er mindre afhængig af CYP3A-metabolisering end visse andre kortikosteroider, og generelt er interaktion ikke sandsynlig. 
Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however, the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such medicinal products.
Indlægsseddel: Information til brugeren Riarify 87 mikrogram/5 mikrogram/9 mikrogram inhalationsspray, opløsning beclometasondipropionat/formoterolfumaratdihydrat/glycopyrronium (beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium) 
Package leaflet: Information for the user Riarify 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Sammenlignet med en fastdosiskombination af beclometasondipropionat og formoterol nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 23 % (hyppighed: 0,41 versus 0,53 hændelser pr. patient/år, p = 0,005). 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005).
Den daglige dosis af Riarify svarer til en medium dosis af inhaleret kortikosteroid. 
The daily dose of Riarify corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids.
Riarify 87/5/9 mikrogram inhalationsspray beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium Til inhalation 
Riarify 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Riarify FEV1 før dosering med 81 ml efter 26 ugers behandling og med 63 ml efter 52 ugers behandling. 
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment.
Sammenlignet med tiotropium nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 20 % (hyppighed: 0,46 versus 0,57 hændelser pr. patient/år, p = 0,003). 
Compared with tiotropium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003).
Patienter med svært nedsat leverfunktion 
Patients with severe renal impairment
Riarify 87/5/9 mikrogram inhalationsspray, opløsning beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium 
Riarify 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
For trykbeholderen med 180 pust vil der blive frigivet en dosis af opløsningen, hver gang patienten trykker på trykbeholderen, og dosistælleren roterer lidt. 
For the 180 actuation pressurised container, each time the patient presses the pressurised container a puff of the solution is released and the counter rotates by a small amount; the number of puffs remaining is displayed in intervals of 20.
Hjælpestoffer: vandfri ethanol, saltsyre, drivmiddel: norfluran. 
Excipients: anhydrous ethanol, hydrochloric acid; propellant: norflurane.
Forud for absorptionen finder der en omfattende konvertering til beclometason-17-monopropionat sted via esteraseenzymerne, der findes i de fleste væv. 
Inhaled beclometasone dipropionate is rapidly absorbed through the lungs; prior to absorption there is extensive conversion to beclometasone 17-monopropionate via esterase enzymes that are found in most tissues.
Den gennemsnitlige halveringstid for elimination af glycopyrronium hos raske frivillige var ca. 6 timer efter i.v.-injektion, mens det varierede fra 5 til 12 timer ved steady state efter inhalation hos KOL-patienter. 
The mean elimination half-life of glycopyrronium in healthy volunteers was approximately 6 hours after i.v.
Angioødem1 
Angioedema1
Hold inhalatoren opret med mundstykket forneden, og placer mundstykket mellem tænderne uden at bide i det. 
Patients should hold the inhaler vertically with its body upwards and place the mouthpiece between their teeth without biting.
Sygdomsforværring 
Deterioration of disease
Farveløs til gullig, flydende opløsning. 
Colourless to yellowish liquid solution.
• nyrebetændelse. 
• inflammation of the kidneys.
• rysten 
• tiredness
Hver leverede dosis indeholder 87 mikrogram beclometasondipropionat, 5 mikrogram formoterolfumaratdihydrat og 9 mikrogram glycopyrronium. 
Each delivered dose contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium.
Sådan skal du bruge Riarify 
How to use Riarify
Patienter med svært nedsat nyrefunktion: 
Patients with severe hepatic impairment
Nedsat knoglemineralsk densitet1 
Bone density decreased1
• ondt i halsen 
• irritation of the throat
Hver afmålte dosis (dosis, der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat, 6 mikrogram formoterolfumaratdihydrat og 10 mikrogram glycopyrronium. 
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium.
moderate eksacerbationer) med 32 % (hyppighed: 0,067 versus 0,098 hændelser pr. patient/år, p = 0,017). 
Compared with tiotropium, Riarify also reduced the rate of severe exacerbations (i.e. excluding moderate exacerbations) by 32% (rate: 0.067 versus 0.098 events per patient/year; p = 0.017).
Hver leveret dosis (dosis, der forlader mundstykket) indeholder 87 mikrogram beclometasondipropionat (beclometasoni dipropionas), 5 mikrogram formoterolfumaratdihydrat (formoteroli fumaras dihydricus) og 9 mikrogram glycopyrronium (glycopyrronium) (som 11 mikrogram glycopyrroniumbromid). 
Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide).
• ørebetændelse 
• inflammation of the ear
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. 
Medicines should not be disposed of via waste water or household waste.
Desuden blev virkningerne sammenlignet med en ekstemporær trippelkombination, der bestod af en fast kombination af to inhalationer af beclometasondipropionat og formoterol 100/6 mikrogram to gange dagligt plus tiotropium 18 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (2.691 randomiserede patienter). 
Study TRINITY compared Riarify with tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily; in addition, effects were compared with an extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (2,691 randomised patients).
Efter udlevering kan inhalatoren opbevares ved temperaturer op til 25 °C i maksimalt 4 måneder. 
After dispensing, the medicinal product may be stored for a maximum of 4 months at a temperature up to 25°C.
• hvis du skal bedøves. 
• if you are due to have an anaesthetic.
• hududslæt, nældefeber, hudkløe 
• skin rash, hives, skin itching
Ethanol, vandfrit Saltsyre 
Ethanol anhydrous Hydrochloric acid Norflurane (propellant)
Nyrer og urinveje Dysuri, urinretention, nefritis1 
Dysuria, urinary retention, nephritis1
Hver afmålte dosis (der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat, 6 mikrogram formoterolfumaratdihydrat og 10 mikrogram glycopyrronium (som 12,5 mg glycopyrroniumbromid). 
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms of glycopyrronium bromide).
Hver afmålte dosis (dosis, der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat (beclometasoni dipropionas), 6 mikrogram formoterolfumaratdihydrat (formoteroli fumaras dihydricus) og 10 mikrogram glycopyrronium (glycopyrronium) (som 12,5 mikrogram glycopyrroniumbromid). 
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms glycopyrronium bromide).
Otosalpingitis1 
Restlessness1
Træthed1 
Fatigue1
• betændelse og rødme i svælget 
• inflammation and redness of the pharynx
• træthed 
• numbness